Company Filing History:
5 out of 761 
1 out of 3,539 
Years Active: 2002-2025
Title: Amy R. Howell: Innovating Cancer Treatment Through Patented Discoveries
Introduction: Amy R. Howell, a talented inventor based in Tolland, Connecticut, has made significant contributions to the field of biomedical research. With a total of five patents to her name, her work primarily focuses on developing innovative compounds that enhance immune responses and improve treatments for serious medical conditions, including cancer.
Latest Patents: Among her latest patents is a groundbreaking invention titled "3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof." This invention discloses new compounds that activate Type II NKT cells, potentially leading to novel cancer treatments. Another notable patent, "Substituted oxetanes, method of making, and method of use thereof," involves oxetane-containing nucleosides that are aimed at addressing disorders related to nucleoside analogs. This patent highlights the therapeutic applications of these compounds in treating cellular proliferation disorders and infections.
Career Highlights: Amy Howell has had a distinguished career, including her association with the University of Connecticut, where she contributed her expertise to various research projects. Additionally, she has worked with the Government of the United States, as represented by the Secretary of the Department of Health and Human Services, demonstrating her commitment to public health and innovation.
Collaborations: Throughout her career, Amy has collaborated with notable colleagues such as Stewart K. Richardson and Rosa C. Taboada. These collaborations have enriched her research and helped bring her innovative ideas to fruition.
Conclusion: Amy R. Howell is an inspiring figure in the realm of medical innovation. Her work has the potential to impact cancer treatments significantly, showcasing the importance of research and patents in advancing healthcare solutions. With her continued dedication to innovation, we can anticipate further contributions from her in the future.